Longeveron Inc. (LGVN)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Joshua Michael Hare FACC, M.D. | Co-Founder, Chief Science Officer & Chairman | 600.62k | -- | 1963 |
| Mr. Mohamed Wa'el Ahmed Hashad M.B.A. | CEO & Director | 1.01M | -- | 1962 |
| Ms. Lisa A. Locklear M.B.A. | CFO, Executive VP & Treasurer | 653.39k | -- | 1962 |
| Mr. Paul T. Lehr J.D. | General Counsel & Secretary | 748.51k | -- | 1968 |
| Mr. Devin Blass | CTO & Senior VP of Chemistry, Manufacturing, and Controls | -- | -- | 1986 |
| Dr. Nataliya Agafonova M.D. | Chief Medical Officer | -- | -- | 1970 |
| Ms. Lisa McClain-Moss | Vice President of Manufacturing | -- | -- | 1971 |
| Mr. Brian G Rash Ph.D. | VP of Research & Discovery | -- | -- | -- |
| Ms. Heather Zhou | VP & Corporate Controller | -- | -- | -- |
Longeveron Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 25
Description
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
April 2, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission